Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions

Lymphoma, Extranodal NK-T-Cell

Interventions

DRUG

Selinexor, anti-PD-1 antibody plus Golidocitinib

Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT06573138 - Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | Biotech Hunter | Biotech Hunter